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Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus 
Abstract 
The recent emergence and re-emergence of alphaviruses, in particular the chikungunya virus (CHIKV), in 
numerous countries has invoked a worldwide threat to human health, while simultaneously generating an 
economic burden on affected countries. There are currently no vaccines or effective drugs available for 
the treatment of the CHIKV, and with few lead compounds reported, the vital medicinal chemistry is 
significantly more challenging. This study reports on the discovery of potential inhibitors for the nsP3 
macro domain of CHIKV using molecular docking, virtual screening, and molecular dynamics simulations, 
as well as work done to evaluate and confirm the active site of nsP3. Virtual screening was carried out 
based on blind docking as well as focused docking, using the database of 1541 compounds from NCI 
Diversity Set II, to identify hit compounds for nsP3. The top hit compounds were further subjected to 
molecular dynamic simulations, yielding a greater understanding of the dynamic behavior of nsP3 and its 
complexes with various ligands, concurrently confirming the outcomes of docking, and establishing in 
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The recent emergence and re-emergence of alphaviruses, in particular the chikungunya virus 
(CHIKV), in numerous countries has invoked a worldwide threat to human health, while 
simultaneously generating an economic burden for affected countries. There are currently no 
vaccines or effective drugs available for the treatment of the CHIKV, and with few lead compounds 
reported, the vital medicinal chemistry is significantly more challenging. This study reports on the 
discovery of potential inhibitors for the nsP3 macro domain of CHIKV using molecular docking, 
virtual screening and molecular dynamics simulations, as well as work done to evaluate and 
confirm the active site of nsP3. Virtual screening was carried out based on blind docking as well as 
focused docking, using the databases of 1541 compounds from NCI Diversity Set II, to identify hit 
compounds for nsP3. The top hit compounds were further subjected to molecular dynamic 
simulations, yielding a greater understanding of the dynamic behavior of nsP3 and its complexes 
with various ligands, concurrently confirming the outcomes of docking, and establishing in silico 
lead compounds which target the CHIKV nsP3 enzyme. 
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Chikungunya virus (CHIKV) is an emerging mosquito-borne arthrogenic member of the alphavirus 
genus from the family Togaviridae, which has caused widespread outbreaks of debilitating human 
disease in the last 5 years [1]. The resulting chikungunya fever (CHIKF) was first described in 1952 
[2], and has been identified in nearly 40 countries. It was listed in 2008 as a US National Institute of 
Allergy and Infectious Diseases (NIAID) category C priority pathogen due to its high morbidity and 
mortality rates and thus major impact on health [3,4]. 
 
After the initial mosquito bite, symptoms of chikungunya fever infection generally start in 4–7 
days, and usually occur in two phases: an acute followed by a second persistent (chronic) stage that 
causes disabling polyarthritis [5]. Acute infection lasts 1–10 days and is characterized by a painful 
polyarthralgia, high fever, asthenia (weakness), headache, vomiting, rash, and myalgia [6]. The 
persistent chronic stage of CHIKF is characterized by polyarthralgia lasting from weeks to years 
[7]. Additional symptoms include neurological disorders such as encephalitis, myeloneuropathy, 
peripheral neuropathy, myelopathy and myopathy [8]. 
 
The CHIKV genome consists of a single stranded, positive-sense RNA genome with two open 
reading frames (ORFs) [9], and is approximately 11.8 Kb in size. The ORF at the 5ʹ end encodes 
two polyproteins, the precursors of the non-structural proteins. The second ORF at the 3ʹ end 
encodes the structural proteins, the capsid (C), envelope glycoproteins E1 and E2 and two small 
cleavage products (E3, 6K). CHIKV starts its life cycle by entering the target host cells through pH-
dependent endocytosis via a receptor-mediated interaction [10] in an analogous manner to other 
members of the Alphaviruses genus. 
 
The medicinal chemistry of CHIKV has recently been reviewed [11]. That review highlighted the 
extreme lack of available chemotherapeutics that show any inhibitory effects against the virus. In 
contrast, the emergence of numerous models and solved crystal structures of CHIKV proteins 
points to enormous possibilities for directed drug design. Notable among the available targets are 
the envelope proteins [12-15] and the non-structural proteins of CHIKV, which play an important 
role in the formation of the transcription/replication complex of the virus [15,16]. Among these, 
nsP3 is considered an attractive target for drug design because of its participation in the early stage 
of the transcription process of viral replication, even though the specific functions, roles, and 
activities of the nsP3 protein remain elusive [16,17].  
 
To date, there have been relatively few studies on the functions, roles and activities of alphavirus 
nsP3 proteins [11,18-20]. Studies based on the Sindbis virus reported that nsP3 phosphoprotein is 
an essential component of the viral replication and transcription process. Functional analysis of the 
effects of mutations of nsP3 on the RNA synthesis demonstrated that the mutations can cause a loss 
of capacity for minus-strand synthesis or a failure to increase plus-strand synthesis. Strikingly, a 
change in G4303 implying an alteration from Gly to Ala68 and leading to a modification to the His-
Ala-Val peptide was predicted to form part of the active site of the conserved nsP3 macro domain 
[19]. However, no effect of the mutations on the ADP-ribose binding site was found [17]. The nsP3 
protein consists of two domains, the N-domain and the C-domain [16,17]; the N-domain is highly 
conserved but the C-domain is not [17]. The C-domain is phosphorylated at up to 16 positions on 
serines and threonines [11,17]. The role of this phosphorylation is still not clear, but deletion of the 
residues involved in the phosphorylated process can decrease the level of RNA sysnthesis 
[11,17,21]. The N-domain, in which the region comprising the first 160 residues is called the X-
domain or a macro domain , is commonly present in eukaryotic organisms, bacteria, archea and in 
many positive-strand RNA viruses such as hepatitis E, rubella, coronavirus and alphaviruses [16]. 
The alphavirus macro domain has a highly positive charged patch on the surface of the protein at 
the crevice of ADP-ribose 1"-phosphate active site and its periphery [17]. The other side of the 
protein, far from the active site, possesses a negative charge. Thus, the nsP3 macro domain is 
considered to complex with ADP- ribose derivatives and RNA. It is also believed to control the 
metabolism of ADP-ribose 1"-phosphate and/or other ADP-ribose derivatives with regulatory 
functions in the cell [11,22]. 
 
The crystal structure of the nsP3 macro domain of CHIKV was solved in 2010 [17]. The 
asymmetric unit of CHIKV includes four molecules. The macro domain consists of six-stranded β-
sheets and four α-helices, and the positions of the α-helices are highly conserved. Also present is 
the ligand ADP-ribose, and the active site of nsP3 macro domain is considered the binding site for 
this ADP-ribose ligand [16,17]. This crevice is at the top of the β-strands 2, 4 and 5 and is 
surrounded by two loops between β2-α1 and β5-α3. Since there is very little information available 
on the nsP3 macro domain and its inhibitor, the current study used computational approaches 
(including molecular docking and virtual screening) to discover potential compounds that inhibit 
nsP3 in CHIKV. Furthermore, in order to understand both the static structures and the dynamic 
information, molecular dynamics simulations were performed to gain a greater understanding of the 
behavior of nsP3 and how it changes upon the binding of small molecules. The results of the study 
were analyzed and compared with previous data to gain a deeper understanding of the atomic 
structure of the nsP3 macro domain and its complexes, as well as to confirm the interactions and 
results from docking. 
 
Material and methods 
 
Molecular docking and virtual screening 
 
Molecular docking and virtual screening were conducted using AutoDock Vina (version 1.5.4) [23]. 
In the current study, the protein was treated rigid while the ligands were fully flexible. The protein 
was prepared by retrieving the 3D crystal structure of the nsP3 macro domain protein from the 
Protein Data Bank (PDB id: 3GPG) and this was used as the receptor for docking. The ligand ADP-
ribose was extracted from the complex crystal structure (PDB id: 3GPO) whereas other ligands 
employed for virtual screening were downloaded from the website of the Diversity Set II chemical 
library of the National Cancer Institute (NCI). This library was selected as it contains diverse drug-
like compounds and potential hits can be ordered from the Open Chemical Repository Collection 
for activity testing. The protein was subsequently minimized by applying the CHARMM force field 
in the Accelrys Discovery Studio 2.0 software package [24]. The steepest-descent algorithm with 
3,000 steps was used to relax the structure and remove steric overlaps. With a Cα RMSD of 0.59 Å 
between the minimized structure and the X-ray structure, the minimized structure was utilized for 
the docking process. Polar hydrogen atoms were added and the Kollman charges were defined with 
AutoDock Tools (version 1.5.4). The key docking parameters include the location of the docking 
site (center x, y, z) and the size of the grid box. The docking protocol was established by re-docking 
the ADP-ribose into nsP3 as seen in the co-crystal structure (3GPO). In the docking with ADP-
ribose, box dimensions of 16×16×16 Å was used, centered at the crystallographically determined 
binding site. In virtual screening, the location and the size of the grid box were carefully 
investigated via blind docking (in which the box is sufficiently large to cover the whole protein) and 
focused docking (in which a smaller box was centered on the potential binding site of interest). 
Blind docking can reveal potential binding sites in nsP3, but it can also suffer convergence 
problems during sampling. The MetaPocket program was also used to predict potential binding sites 
of nsP3 other than the active site [25]. After docking, the results were analyzed and compared with 
available experimental data. The top ten compounds (“hit”) were identified according to their 
binding affinities using the default scoring function in Vina. The modes of interaction between l the 
igands and the protein were analyzed in Accelrys Discovery Studio 2.0. The drug-like properties of 
these compounds were subsequently evaluated using the Lipinski Guidelines [26]. 
 
 
Molecular dynamics simulations of the docked complexes 
 
In order to evaluate the stability of the docked complex and better characterize the ligand-nsP3 
interactions, equilibrium molecular dynamics (MD) simulations were carried out with the NAMD 
package [27]. The protein atoms were treated with the CHARMM22 force field [28], and the 
corresponding parameters for the ligands were generated with AmberTools [29]. MD simulations 
were carried out for the apo state (PDB id: 3GPG) and the five ligand-nsP3 complexes. The systems 
were solvated in a cubic box of TIP3P water molecules and neutralized by sodium counterions to 
achieve the physiological ionic concentration of 0.15 M with NaCl. The total number of atoms 
(including protein, water and counterions) in the CHIKV system was about 18,000, and the size of 
water box was about 58×58×58 Å. All simulations were performed under the periodic boundary 
conditions at a temperature of 298.15 K and a pressure of 1 atm. Temperature and pressure coupling 
were maintained with the Langevin algorithm. A particle mesh Ewald algorithm was used to 
calculate the electrostatic interactions [30]. The cutoff distance for van der Waals interactions and 
the pairlist distance were 12 and 13.5 Å, respectively. The systems were minimized and then 
equilibrium simulations with weak harmonic restraints on the heavy atoms were performed for 3 ns. 
The production runs were continued for 20 ns. The trajectories were saved every 1 ps. The resulting 




Validation of the docking protocol by re-docking with ADP-ribose 
 
The docking protocol was evaluated by re-docking ADP-ribose into nsP3, and the outcome was 
compared with the available co-crystal structure (PDB id: 3GPO). The ligand conformations were 
ranked in terms of their predicted binding affinities using the default scoring function in Vina (see 
Table S1 of the “Electronic supplementary material,” ESM). The best-docked pose had a binding 
affinity of -10.2 kcal mol
-1
. The hydrogen bonds formed between ADP-ribose and nsP3 are shown 
in Fig. 1. It is evident that there were interactions with 11 residues in the active site of nsP3: Ile11, 
Ala23, Asn24, Asp31, Val33, Leu108, Gly112, Val113, Tyr114, Tyr142 and Arg144. Most of the 
hydrogen-bond donors came from the protein residues, with the corresponding acceptors deriving 
from the ADP-ribose. In addition, the diphosphate component of ADP-ribose showed the strongest 
interaction of any part of this ligand.  
 
Moreover, the accuracy and reliability of docking was evaluated by superimposing the docked 
structure on the co-crystal structure. The heavy-atom root mean square deviation (RMSD) was 0.6 
Å, smaller than the 2.0 Å often used as a criterion in correct bound structure prediction [33] (Table 
S1 of the ESM and Fig. 2) indicating that the molecular docking reproduced the binding mode in 
the co-crystal structure. Comparison of the interactions indicated by the docking results with 
published data (Table 1) confirmed there was good agreement in the key interactions and showed 
that this docking protocol was able to reproduce the correct pose (Fig. 2). 
 
Identification of potential inhibitors using virtual screening 
 
In an effort to identify potential inhibitors (hit compounds), 1541 compounds in NCI Diversity Set 
II were screened by docking them with the nsP3 of CHIKV. Virtual screening (VST) was carried 
out using three different setups. The first was a focused docking centered around the ADP-ribose 
binding site (pocket 1: VST1 and VST2). The second setup was a blind docking centered either at 
the middle of the ADP-ribose binding site (VST3) or the protein (VST4) with the box made large 
enough to cover the whole protein. The third setup was a focused docking centered on the binding 
sites predicted by MetaPocket (pocket 2: VST5; pocket 3: VST6). The top ten compounds for each 
VST based on their binding affinities are listed in Table S2 of the ESM.  
 
In the focused dockings that targeted binding pocket 1 (the ADP-ribose binding site; VST1 and 
VST2), the top hits were NCI_25457 (-10.8 kcal mol
-1
) and NCI_345647_a (-10.9 kcal mol
-1
). 
Among the top ten hits, four are shared between VST1 and VST2, which differ in the size of the 
grid box used. Given our interest in finding more inhibitors as well as other potential binding sites 
in the structure of nsP3, we used the blind docking to dock into the entire protein, with the grid box 
centered on the middle of either the ADP-ribose binding site (VST3) or the protein (VST4). For the 
blind docking (VST3 and VST4), six of the top ten hits are common to VST3 and VST4, and the 
binding affinities were reproduced to within 1.0 kcal mol
-1
. This indicates that the blind dockings 
are likely to have converged. The results show that most of the top ten hits fitted well in pocket 1, 
and this pocket can accommodate ligands of different sizes. However, ligands having bulky 
structures, such as NCI_293778, NCI_58052 and NCI_61610 (common to the top ten hits of both 
VST3 and VST4), protruded from the binding site. Furthermore, the other pockets surrounding 
pocket 1 may serve as alternative binding sites for potential inhibitors.  
 
By comparing the results from the blind dockings with the pockets predicted for nsP3 using 
MetaPocket, pocket 2 and pocket 3 were identified, and focused docking at pockets 2 (VST5) and 3 
(VST6) was conducted. Screening at VST5 and VST6 produced hits that had already been 
identified in previous screens, along with some new hits (Table S2 of the ESM). Pockets 1 and 3 
share a number of interacting residues, including Asn24, Asp31, Val33, Gly112, Val113 and 
Tyr114. In contrast, pocket 2 was located on the opposite side and behind pocket 1, and comprised 
the residues His1, Pro2, Ser3, Tyr4, Met132, Asp133, Ser134, Thr135, Asp136, Ala137, Asp138, 
Val139, Arg159, Thr160, Ile156 and Gln157. The location of the pockets in nsP3 and the location 
of the different ligands in the three pockets are illustrated in Figs. 3 and 4. Most of compounds 
effectively occupy pockets 2 and 3 and participate in significant interactions. Ligands NCI_127133 
(-8.3 kcal mol
-1
) and NCI_670283 (-10.6 kcal mol
-1
) bind in pockets 2 and 3 as well as pocket 1, but 
in different conformations. Interestingly, the ligand NCI_293778 would be able to bind into all 
three pockets, although it may be inferred that the pocket 1 is more favorable for binding, with a 
binding affinity of -10.5 kcal mol
-1
 compared to -9.4 kcal mol
-1
 (pocket 3) and -8.3 kcal mol
-1
 
(pocket 2).  
 
For the virtual screening, it is worth mentioning that the changes in size of the grid box and its 
location affected the search process in Vina. Increasing the dimensions of the box is likely to be 
better suited to larger molecules. For instance, in the blind docking (VST3 and VST4), NCI_61610 
(-11.1 kcal mol
-1
) was identified as a top ten hit, but it is not one of the top ten hits for VST1 and 
VST2. The locations of the three binding sites along with the top five compounds obtained from 
VST are displayed in detail in Fig. 3 (for more information, see Fig. S1 of the ESM). It is also 
interesting that the majority of the hit compounds show tighter binding in pocket 1 than in pocket 2. 
Detailed analyses of the interactions between the ligands and protein target were carried out by 
characterizing the hydrogen bonds and hydrophobic contacts [34]. The results show that hydrogen-
bonding interactions play a more important role in the binding to pocket 1, whereas  hydrophobic 
contacts are responsible for the interactions associated with the binding to pocket 2. In agreement 
with this, it was previously reported [16] that the residues Ser110, Thr111, Gly112 and Tyr114 
define pocket 1 and are key residues in interactions with ligands. In addition, we found that these 
residues also define pocket 3. 
  
Investigation into the stability of the protein and its complex using molecular dynamics simulations 
 
The top five hit compounds NCI_61610, NCI_25457, NCI_345647_a, NCI_670283 and 
NCI_127133 from each screening were subsequently subjected to molecular dynamics simulations 
(Table 2). MD simulations were undertaken to investigate the dynamic behaviors of protein nsP3 
and its complexes and to obtain the precise binding modes [35]. MD simulations were carried out 
with the NAMD package with the CHARMM force field for 20 ns following 3 ns of equilibrium 
simulations. 
 
In order to assess the overall stability, RMSD values with respect to the starting structure were used 
as the major criterion. The backbone RMSD curves for nsP3 and its complexes with different 
ligands with respect to the starting structure were not significantly different from each other (Fig. 
5). All systems were relatively stable throughout the simulations after reaching equilibrium within 3 
ns. Hence, data taken from the trajectories in the last 20 ns will be used for further analysis.  
 
The root mean square fluctuation (RMSF) of the Cα atoms of each residue was calculated using the 
data from 20-ns trajectories of the protein nsP3 and its complexes (Fig. 6). The RMSF profiles of 
the apoprotein and the complexes were similar. However, subtle differences were observed for a 
few regions, including the loop at residues 31-34. The residues comprising the binding pockets 
were quite stable during the simulations, with fluctuation of < 1.0 Å. It is worth noting that when 
the three ligands NCI_61610, NCI_25457 and NCI_345647_a were bound to the protein at pocket 
1, the RMSFs for the binding loop region 31-34 were noticeably smaller than those seen for the  
apoprotein. The RMSF for this loop was not significantly perturbed when the ligands NCI_670283 
and NCI_127133 were bound to pockets 3 and 2, respectively.  
 
Interaction between the ligands and the protein nsP3  
 
A detailed analysis of the hydrogen-bonding (H-bond) interactions and hydrophobic contacts 
between the ligands and nsP3 was carried out. Simple geometric criteria were used to define a 
hydrogen bond: a distance between proton donor (D) and acceptor (A) atoms of <3.5 Å and an 
angle D-H…A of >120
0
 [16]. If the H-bond occupation percentage was >50%, they were 
considered to arise from the medium, whereas strong hydrogen bonds are considered to be present 
for H-bond occupations of greater than 75% [16]. Hydrophobic contacts between the carbon atoms 
of non-polar parts of protein residues were also monitored, with a cutoff distance of 4.0 Å assumed 
[36,37].  
 
Complementary to the results of the docking (where the protein was kept rigid), molecular 
dynamics simulations revealed that when the ligands bind to nsP3, the ligand or/and the residues in 
the binding pockets fluctuate, with the residues adapting their structures to better accommodate the 
ligands by forming H-bonds and/or hydrophobic contacts. This can be illustrated by superimposing 
the complex before the simulations (at 0 ns) on the complex after the simulation (at 23 ns);  see Fig. 
7). Not surprisingly, the figure shows that some residues, such as Val33, Val113, Tyr114, Arg144 
and Trp148 (for ligands binding to the pocket 1; see Fig. 7a, 7b and 7c), display noticeable 
movement upon binding. For ligands NCI_127133 (pocket 2) and NCI_670283 (pocket 3), the 
results showed that the fluctuations of residues Ala1, Pro2 and Tyr4 (in the pocket 2) and residues 
Ala22, Val33, Val113 and Tyr114 (pocket 3) were required for a correct fit into nsP3. 
 
Key residues forming hydrogen bonds and hydrophobic contacts between nsP3 and ligands 
 
Hydrogen-bonding analyses revealed that the binding of each investigated ligand to the protein is 
stabilized by a number of hydrogen bonds, except ligand NCI_127133 (Table 3). We can infer that 
the binding site at pocket 1, where NCI_61610, NCI_25457 and NCI_345647_a bind, is the most 
favorable place for ligands to form hydrogen bonds (Fig. 8). There are three strong hydrogen bonds 
between ligand NCI_61610 and residue Asn24 (98%), Tyr114 (92%) and Gly112 (88%) in pocket 
1, but only one strong and one moderately hydrogen bond between NCI_670283 and Thr111 (78%) 
and Gly112 (66%) in the pocket 2 (Fig. 7). In contrast, pocket 3 is unlikely to be favored for 
binding, as no H-bonds with occupations of >10% were identified.  
 
Furthermore, the residues in the region 110-114 of the protein are key residues that are responsible 
for forming the hydrogen bonds between the protein and the ligands in binding pockets 1 and 3. 
Most of them serve as hydrogen bond donors, except in the complex nsP3-NCI_61610, where 
residue Thr111 serves as an acceptor. This observation is in close agreement with the results of 
earlier simulations and experimental data [16]. In addition, it emerged that the structures of 
NCI_61610 and NCI_345647_a are more polar than the other ligands, so more hydrogens bonds 
were found in complexes involving them than in complexes involving the other ligands.  
 
The nsP3 residues that were found to interact with the ligands through hydrophobic contacts are 
listed in Table 4. It is worth noting that four residues, namely Val33, Val113, Tyr114 and Trp148, 
play a crucial role in stabilizing the complexes by facilitating hydrophobic interactions between the 
ligands and nsP3 at the binding pockets 1 and 3, while Ala1, Pro2 and Tyr4 are important in pocket 
2. The solvent accessible surface areas (SASA) were calculated to monitor the possible changes in 
the salvation environment upon ligand binding (Table 5). We expected to see that the SASA for 
hydrophobically interacting residues in the protein-ligand complex will decrease compared to those 
in apoprotein. In pocket 1, when the ligands bind to protein, it can be seen that the solvent surface 
of residue Tyr114 decreases from 70.2 Å
2 
in the apo nsP3 to 63.4 Å
2
 for the nsP3-NCI_61610 
complex and 63.8 Å
2
 for nsP3-NCI_345647_a complex. Also, the SASA of Val33 reduces from 
68.8 Å
2
 in the apo state to 57.4 Å
2
 and 52.9 Å
2
 for the bound state in nsP3-NCI_25457 and 
NCI_345647_a, respectively. However, it is apparent that the changes in SASA for Val33, Val113 
and Trp148 are not consistent for different ligands. This can be rationalized by noting that these 
residues are able to form not only hydrophobic contacts but also polar hydrogen-bonding 
interactions. Thus, the change in SASA is compromised by polar interactions, and both types of 
interaction modulate the SASA.  
 
In order to probe the effects of the static protein structure used in the docking, multiple docking 
simulations and virtual screening were carried out based on the sampled conformations of protein 
nsP3-NCI_61610 at different simulations times (5, 10, 15, and 20 ns). These results are listed in 
Tables S3 and S4 of the ESM. The binding affinities observed in these docking runs (Table S3 of 
ESM) were not significantly different from those obtained in previous dockings based on the X-ray 
structure. Additionally, the binding modes observed in the dockings based on the X-ray structure 
are similar to those obtained based on the MD sampled structures. Most of the top hits in the virtual 
screening were the same compounds as those identified in the previous screening, although there 
were some new hits too. This indicates that the docking results were similar for different static 
structures of the nsP3 protein. 
 
Discussion and conclusion 
 
So far, little information on the nsP3 macro domain and its inhibitors has been reported. The present 
study is of great importance in relation to identifying novel inhibitors of the chikungunya virus. It is 
also the first to combine molecular docking, virtual screening and molecular dynamics simulations 
to identify potential inhibitors that target CHIKV by taking advantage of the recently determined 
high-resolution crystal structure of nsP3 in complex with ADP-ribose. Considering the presence of 
positive charge at the ADP-ribose binding site, this binding pocket may have the tendency to 
accommodate negatively charged ligands, which may not have acceptable pharmacokinetic 
properties. Therefore, we decided to identify all possible binding pockets based on the available 
methods.  We first re-docked the ADP-ribose and successfully reproduced the bound structure and 
the key residues for interactions in the ADP ribose binding pocket. It was evident that the binding 
affinity of ADP-ribose was less than -10 kcal mol
-1
, showing that this negatively-charged ligand 
binds very tightly to nsP3. This study also demonstrates that the current docking protocol utilizing 
Autodock Vina is a robust approach for reproducing experimentally determined binding modes.  
 
Subsequently, virtual screening with the NCI Diversity Set II was undertaken to identify potential 
novel inhibitors that target CHIKV. In addition to the well-characterized adenine binding pocket 
(pocket 1), two additional binding pockets (pockets 2 and 3) were identified through blind docking 
and using MetaPocket. Pocket 3 partially overlapped with pocket 1, while pocket 2 was located on 
the opposite side of the protein (Fig. 3). A comparison of the blinding affinities at the three different 
binding pockets revealed that all of the hits for pocket 1 bind to the protein well, with binding 
affinities of less than -10 kcal mol
-1
. This suggests that the pocket 1 is the most favorable for ligand 
binding. In contrast, pocket 2 may not be a good location for binding compared to pockets 1 and 3 
because it is associated with higher binding affinities. It is also interesting to note that some ligands 
were repeated multiple times in the list of virtual screening results. These ligands can bind to 
different pockets in different conformations (e.g.; the ligand NCI_127133 binds to pockets 1 and 2, 
ligand NCI_670283 binds to pockets 1 and 3 and ligand NCI_293778 binds to pockets 1, 2 and 3). 
These ligands may therefore have greater potential for use as inhibitors. 
 
By analyzing the hydrogen bonding and hydrophobic interactions between the ligands and nsP3, 
key residues were identified. The region encompassing residues 110-114 was predicted to be the 
most important area for ligands interactions. This is consistent with the results of previous work by 
Rungrotmongkol et al. [16].  
 
Furthermore, equilibrium molecular dynamics simulations were carried out to validate the 
molecular docking results. Analysis of the simulations confirmed that the docked ligand-nsP3 
complexes were stable during the 20-ns simulation. However, subtle structural rearrangements in 
nsP3 were observed that led to better accommodation of the ligands. MD simulations also 
confirmed that the binding pocket 1 is the favored pocket for ligand binding, considering the 
favorability of the interactions between the ligands and nsP3.  
 
In summary, through a combination of molecular docking, virtual screening and molecular 
dynamics simulations, we identified potential inhibitors of CHIKV based on the targeting of its 
nsP3 macro domain. In the future work, the detailed binding modes for the identified inhibitors will 
be better characterized by performing more computationally extensive free-energy calculations, and 
their inhibitory effects will be verified by experimental studies. Additionally, the present work 
provides useful information for constructing pharmacophores in ligand-based drug design and for 
generating the chemical libraries utilized in the development of novel inhibitors targeting CHIKV.  
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Figure 1. Re-docking ADP-ribose into the active site of nsP3: (A) The best docking pose of 
ligand ADP-ribose is represented as a stick model (colored by atom type) while the protein 
nsP3 is shown in the solvent surface (colored by interpolated charge with a probe radius of 1.4 
Å). (B) The interactions of this pose and nsP3 residues showing hydrogen bonding 







Figure 2. Superimposition of the ADP-ribose after docking (in red, the top pose) on its 
structure in the co-crystal structure (in blue) at the active site of nsP3. The heavy-atom 







Figure 3. Representation of three binding pockets identified in the nsP3: (A) The location of 
three pockets in the nsP3. (B) Illustration of three pockets showing the locations of five top-hit 
compounds obtained from virtual screenings at these binding sites: NCI_25457, 
NCI_345647_a, NCI_61610 (in magenta) at the pocket 1, NCI_127133 (in blue) at the pocket 2 














Figure 4. Illustration of three binding pockets identified in the nsP3. Each illustration 
contains two images: the first shows the protein nsP3 (in red) as a ribbon and the ligand (in 
green) in stick representation, and the second shows the surface of the pocket (in purple) 
surrounding the bound ligand (in green) in stick representation: (A) Pocket 1 with the 
complex nsP3-NCI_61610. (B) Pocket 2 with the complex nsP3-NCI_127133 (structure has 
been rotated 180
0




Figure 5. Backbone RMSD profiles for the apoprotein nsP3 and its complexes of nsP3 with 





Figure 6. RMSFs values of the Cα atoms of the apoprotein nsP3 and its different complexes, 








Figure 7. Superimposition of complex structures observed at 0 ns (in blue) and 23 ns (in red) 
with the structures represented as ribbons, the ligands as van der Waals surfaces, and the 
residues surrounding the ligands as sticks: (A) Apoprotein nsP3. (B)-(F): Complexes of nsP3 










Figure 8. Hydrogen-bonding interactions between nsP3 and NCI_61610 and NCI_670283: (A) 
The complex of nsP3 with ligand NCI_61610 involves three strong H-bonds with residues 
Asn24, Tyr114 and Gly112. (B) The complex of nsP3 with ligand NCI_670283 involves one 













Table 1. Comparison of the hydrogen-bonding interactions inferred for the nsP3-ADP-ribose 
docked complex with previously published data. In [17], key residues were identified by 
performing an experimental study of the crystal structures of the complex nsP3-ADP-ribose 
(3GPO), while residues reported in [16] were determined by realizing molecular dynamics 
simulations of ADP-ribose in nsP3, based on the above crystal structures. 
 
 Current work Ref [17] Ref [16] 
HBs 11 11 11 








































































LogP: An octanol-water partition coefficient; H-D: Hydrogen donor; H-A: Hydrogen acceptor; 
MW: Molecular weight. 
 
 
Table 3. Analysis of the hydrogen bonds that occurred during the trajectories sampled in the 
MD simulations. 
 
 Number of H-bonds Details of H-bonds % occupancy 
NCI_61610 5 Asn24 (HD22)-O1  98 
Tyr114 (HN)-O 92 
Gly112 (HN)-O 88 
Thr111 (OG1)-H1 13 
Cys34 (HG1)-O1 10 
NCI_25457 3 Val113 (HN)-N 29 
Val33 (HN)-N 21 
Val33 (HN)-O 20 
NCI_345647_a 7 Ile11 (HN)-O4 39 
Ile11 (HN)-O6 12 
Gly112 (HN)-O1 18 
Val33 (HN)-O 17 
Gly32 (O)-O5 14 
Thr111 (HN)-O1 13 
Arg144 (HE)-O3 10 
NCI_670283 4 Thr111 (HN)-O 77 
Gly112 (HN)-O 65 
Ser110 (HN)-O 25 
Thr111 (HG1)-O 10 
NCI_127133 0 No H-bonds with occupancy more than 10% 
 
 
Table 4. Analysis of hydrophobic contacts during the trajectories sampled in the MD 
simulations. 
 
Ligand Number of 
interacting 
residues  
Name of non-polar residues interactions 
NCI_61610 8 Ala22, Pro25, Leu28, Val33, Pro107, Val113, Tyr114, Trp148 
NCI_25457 6 Ala22, Val33, Pro107, Val113, Tyr114, Trp148 
NCI_345647_a 6 Ile11, Val33, Ala36, Val113, Tyr114, Trp148 
NCI_670283 6 Ala22, Leu28, Val33, Pro107, Val113, Tyr114 































Ala22 31.3 36.6 35.6 
 
45.0 
 Pro25 75.5 57.8 
    Leu28 102.6 108.2 
  
100.8 
 Val33 68.8 81.7 57.4 52.9 79.7 
 Pro107 25.9 20.4 25.2 
 
24.1 
 Val113 129.8 146.5 138.8 130.8 142.2 
 Tyr114 70.2 63.4 69.3 63.8 87.4 
 Trp148 84.0 88.4 90.2 95.5 
  Ile11 12.6 
  
25.8 
  Ala36 34.0 
  
30.0 
  Ala1 74.5     81.2 
Pro2 37.9     56.4 






Table S1. List of poses in the docking of ADP-ribose into nsP3. RMSD refers to the heavy-
atom root mean square deviation from the co-crystal structure for ADP-ribose. 
 
Poses Binding affinity (kcal/mol) RMSD (Å) 
1 -10.2 0.6 
2 -8.9 8.6 
3 -8.9 1.8 
4 -8.9 5.5 
5 -8.6 8.4 
6 -8.5 4.4 
7 -8.4 0.6 
8 -8.3 0.6 



















Table S3. Re-docking results for complex nsP3-NCI_61610 with different conformations of 
nsP3 taken from the different times of simulations at the pocket 1. 
 
nsP3 conformation Binding affinity 
(kcal/mol) 
Interaction between the inhibitor and 
residues of protein (with distance in Å) 
At 0ns -11.1 Tyr114(HH)-N=2.0 
Val33(HN)-O=2.3 
Asn24(HD21)-O=2.4 
At 5 ns -10.3 Tyr114 (OH)-H1=1.9  
At 10 ns -11.3 Asn24 (HD22)-O=2.1  
Tyr114 (OH)-H1=2.3  
At 15 ns -10.6 Asn24 (HD22)-O1=2.5  
Ser110 (HN)-O=1.9 
At 20 ns -11.4 Tyr114 (OH)-H1=2.3 
 
 
VST1 VST2 VST3 VST4 VST5 VST6 
Fit at the center 
of binding site  
Center_x = 9.7 
Center_y =43.0 
Center_z = -13.2 
Fit at the center 
of binding site  
Center_x = 9.7 
Center_y = 43.0 
Center_z = -13.2 
Fit at the center 
of binding site  
Center_x = 9.7 
Center_y = 43.0 
Center_z = -13.2 
Fit at the center 
of protein  
Center_x = 7.7 
Center_y = 45.3 
Center_z = -5.3 
Fit at the 
prediction 
pocket 2 
Center_x = 7.7 
Center_y = 45.4 
Center_z = 11.5 
Fit at the 
prediction 
pocket 3 
Center_x = 2.3 
Center_y = 44.6 
















































































































































Table S4. Virtual screening results for blind docking into the pocket 1 with different 





VST-5ns VST-10ns VST-15ns VST-20ns 
Fit at the center of 
binding site  
Center_x = 9.7 
Center_y =43.0 
Center_z = -13.2 
Fit at the center of 
binding site  
Center_x = 9.7 
Center_y = 43.0 
Center_z = -13.2 
Fit at the center of 
binding site  
Center_x = 9.7 
Center_y = 43.0 
Center_z = -13.2 
Fit at the center of 
binding site  
Center_x = 9.7 
Center_y = 43.0 
Center_z = -13.2 
Cover binding site 
Size 20×20×20 
Cover binding site 
Size 20×20×20 
Cover binding site 
Size 20×20×20 






















































































Figure S1. Structure of nsP3 with location of three binding sites at the different virtual 
screenings: (A) VST1; (B) VST2; (C) VST3; (D) VST4; (E) VST5; (F) VST6. 
